Follicular Lymphoma highlights of the ASH 2023 Congress
Professor Carla Casulo summarizes the most important highlights in the field of Follicular Lymphoma treatment after the 65th American Society of Hematology Annual Meeting.
Highlights of the ASH 2023 Congress
Professor Mikkael Sekeres summarizes the most important highlights that presented at the 65th American Society of Hematology Annual Meeting.
Present and future of Multiple Myeloma management
Professor Xavier Leleu explains the present and future of Multiple Myeloma management, how new regiments, new treatments will change how we treat patients.
Ibrutinib-Venetoclax Combination Found Effective Against Mantle Cell Lymphoma
Professor Michael Wang explains their findings that combining ibrutinib and venetoclax improves progression-free survival and remission rates in patients with mantle cell lymphoma.
Real-World Outcomes With Brexucabtagene Autoleucel
Professor Swetha Kambhampati on Mantle Cell Lymphoma: Real-World Outcomes With Brexucabtagene Autoleucel.
Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia - report from ASH2023
Professor on frontline treatment with targeted agents in patients with Chronic Lymphocytic Leukemia.
Dramatically Worse Myeloma Outcomes in Real World vs. Trials
Dr. Alissa Visram on the presented the data during 65th American Society of Hematology Annual Meeting. Patients with multiple myeloma who were treated in the real world had 44% worse progression-free survival and 75% worse overall survival than patients treated on clinical trials, according to a pooled analysis of efficacy versus effectiveness for seven MM regimens.
Multiple Myeloma highlights of ASH 2023 Congress
Professor Andrzej Jakubowiak summarizes the most important highlights in the field of MultiplMyeloma treatment at the 65th American Society of Hematology Annual Meeting.
Chronic Myeloid Leukemia highlights of ASH 2023 Congress
Professor Giuseppe Saglio summarizes the most important highlights in the field of Chronic Myeloid Leukemia treatment at the 65th American Society of Hematology Annual Meeting.
Acute myeloid leukemia highlights of ASH 2023 Congress
Professor Eunice S. Wang summarizes the most important highlights in the field of Acute Myeloid Leukemia treatment at the 65th American Society of Hematology Annual Meeting.
Chronic Myeloid Leukemia: Novel Therapeutic Approaches
Professor Carmen Fava summarizes the therapeutic novelties of Chronic Myeloid Leukemia management at the 65th American Society of Hematology Annual Meeting.
Non-Hodgkin Lymphoma highlights of the ASH 2023 Congress
Professor Umberto Vitolo summarizes the most important highlights in the field of Non-Hodgkin Lymphoma treatment at the 65th American Society of Hematology Annual Meeting.
Diagnostic and Therapeutic Novelties of Multiple Myeloma Management
Professor Enrique Ocio summarizes the diagnostic and therapeutic novelties of Multiple Myeloma management at the 65th American Society of Hematology Annual Meeting.
Acute myeloid leukemia highlights of the ASH 2023 Congress
Professor Agnieszka Wierzbowska summarizes the most important highlights in the field of acute myeloid leukemia treatment at the 65th American Society of Hematology Annual Meeting.
State of the art ALL treatement in 2023
Professor Marlise R. Luskin summarizes the state of the art acute lymphoblastic leukemia treatement at the 65th American Society of Hematology Annual Meeting.
Revumenib Found Effective Against High-Risk KMT2Ar Acute Leukemia
Professor Ibrahim Aldoss explains that patients with relapsed or refractory acute leukemia with rearrangement in the lysine methyltransferase 2a gene, a genetic marker known as KMT2Ar, who were treated with revumenib saw an overall response rate of 63%, according to results from a phase II trial being reported during the 65th American Society of Hematology (ASH) Annual Meeting and Exposition.
Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women
Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the Phase III SOLAR-1 trial
Lifestyle Intervention Helped Breast Cancer Survivors Lose Weight, and Was Associated with Higher Disease-free Survival Rates
Choice of Surgery May Affect Quality of Life for Young Breast Cancer Survivors
Circulating Tumor Cell Count Could Help Choose Treatment for Metastatic Breast Cancer Patients
Axillary Radiotherapy and Lymph Node Surgery Yielded Comparable 10-year Outcomes for Patients with Breast Cancer
Accelerated Partial Breast Irradiation, Although Close, was Not Equivalent to Whole Breast Irradiation To Control Ipsilateral Breast Tumor Recurrence
A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ
PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib
Phase III KATHERINE Clinical Trial Crossed Early Reporting Boundary and Met its Primary Endpoint
Adjuvant Capecitabine Did Not Significantly Improve Outcomes for Patients With Early-stage Triple-negative Breast Cancer
Adjuvant Chemotherapy Might Not Add Benefit in Breast Cancer Patients who Have Excellent Response to Neoadjuvant Chemotherapy
Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer
Low-Dose Tamoxifen Was Safe and Effective at Reducing Recurrence and New Breast Disease for Patients With DCIS, LCIS, and ADH
Increasing the dose intensity of adjuvant chemotherapy: an EBCTCG meta-analysis
Phase Ib/II Study Evaluating Safety and Efficacy of Pembrolizumab and Trastuzumab in Patients with Trastuzumab-Resistant HER2-positive Advanced Breast Cancer: Results from the PANACEA Study (IBCSG 45-13/BIG 4-13/KEYNOTE-014)
Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma
We asked Professor David F. McDermott, investigator of the KEYNOTE-564 study, about the trial and the new data presented on overall survival at ASCO GU 2024.
ESMO 2023 Scientific Chair's welcome and invitation to next year's ESMO Congress
ESMO 2023 Scientific Chair Prof. Silke Gillessen gives a brief summary of this year's congress and invites colleagues to ESMO 2024 in Barcelona next year.
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer
Professor Matteo Lambertini highlights the result of the recently published study about the safety of temporarly interrupting endocrine therapy to attempt pregnancy after #Breastcancer. The preliminary results say, this temporary interruption it does not to apper the risk of the patients recurrence.
Watch the full interview with Dr. Lambertini -> https://medicaldigest.org/scientific-contents/interview:whats-new-treatment-breast-cancer-highlights-esmo-bc-2023
The issue of adjuvant vs neoadjuvant treatment
Professor Paolo Ascierto discusses the issue of adjuvant vs neoadjuvant treatment, so whether it's better to use immunotherapy before or after surgery.
Watch the full interview with Dr. Ascierto -> https://medicaldigest.org/scientific-contents/interview:hot-topics-melanoma-management
The treatment sequence in metastatic melanoma
Professo Paolo Ascierto discusses the treatment sequence in metastatic melanoma, data shows it is better to start with immuno- than targeted therapy.
Watch the full interview with Dr. Paolo Ascierto -> https://medicaldigest.org/scientific-contents/interview:hot-topics-melanoma-management
Functional Precision Medicine in Oncology
What functional precisionmedicine in oncology means? Professor Anthony Letai explains the new diagnostic option - after he chaired an interesting session about the topic at AACR23.
For more information visit the website of SFPM: https://www.sfpm.io/
Watch the full interview with Dr. Anthony Letai -> https://medicaldigest.org/scientific-contents/interview:functional-precision-medicine-oncology
The first mRNA cancer vaccine with pembrolizumab minimizes recurrence rate in melanoma tells Jeffrey Weber clinical investigator
Jeffrey Weber explains the efficacy and safety results of the personalized mRNA cancer vaccine mRNA-4157 with pembrolizumab presented at ACCR23.
It is the first:
- randomized trial that shows benefit for a neoantigen vaccine approach of any type
- trial of a mRNA vaccine in melanoma
- trial in any cancer that was a phase 2 randomized trial where there was a control arm showing benefit for the addition of the neoantigen vaccine to an established approach in this case of course the PD-1 antibody pembrolizumab
Watch the full interview with Dr. Jeffrey Weber -> https://medicaldigest.org/scientific-contents/interview:first-mrna-cancer-vaccine-pembrolizumab-minimizes-recurrence-rate-melanoma-tells-jeffrey-weber-clinical-investigator
Paradigm shift in the early NSCLC? The role of ICIs in the adjuvant treatment
Professor Federico Cappuzzo gave us an update on the emerging data on the field of lung cancer. There are very important news that were presented during the ESMO, ELCC and EACR. These data are clearly changing the standard of care of patients with early stage Non-Small-Cell Lung Cancer. In this field we have data from two very important trial: the IMpower010 and the KEYNOTE-09.
How will the current therapeutic options change the treatment of RCC in the daily practice?
Prof. Camillo Porta shared his thoughts on the ASCO GU 2022 meeting which focused on the renal cell carcinoma updates. Which were those changes what we can apply in our daily practice?
The role of immune checkpoint inhibitors and VEGF TKIs in the adjuvant treatment of renal cell carcinoma
Prof. David F. McDermott shared his thoughts in the kidney cancer filed. What was the biggest changes in the last six months?
Treatment intensification in the treatment of prostate cancer
Professor Oliver Sartor gave us a talk about the newer concepts around the treatment intensification in prostate cancer, focus a little bit on the newer darolutamide and a PARP inhibitor studies.
Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma
Professor Stefan N. Symeonides gave us a talk about the results from 30-month follow-up of KEYNOTE-564.
State of the art treatment of bladder cancer
Professor Matthew R. Zibelman gave us updates in bladder or urothelial cancers after the recent ASCO GU symposium 2022 from San Francisco.
First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer
Professor Ken Kato gave us a talk about longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study.